QUT ePrints

Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity

Feigl, Beatrix, Greaves, Amanda, & Brown, Brian (2007) Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity. Clinical Ophthalmology, 1(2), pp. 1-9.

Abstract

Purpose: To evaluate neuroretinal function and anatomical outcomes in patients with neovascular age-related macular degeneration (AMD) after three treatments with ranibizumab.

Design: Observational case reports.

Methods: We investigated visual function in three patients, one female (80 years) and two male (77 and 74 years) with neovascular AMD. Twenty healthy participants served as control group. We measured visual acuity (Bailey-Lovie charts), contrast sensitivity (Pelli-Robson) and neuroretinal function using the multifocal electroretinogram (mfERG). Central macular thickness was evaluated using optical coherence tomography (OCT). Main outcome measures were central and peripheral mfERG peak to trough (N1P1) response density amplitudes and peak (P1) implicit times. All tests were performed before the first treatment (baseline) and after each of the three treatments with intravitreal 0.3 mg ranibizumab.

Results: Visual acuity and contrast sensitivity remained stable or improved. Central macular thickness decreased after three treatments in all three patients. We found no significant change in central and peripheral neuroretinal function in the AMD patients between pre- and posttreatments 2 and 3. Although the mfERG amplitudes in the AMD patients were not significantly reduced compared with the age-similar group at baseline, there was a statistically significant reduction in central and peripheral mfERG amplitudes after three treatments.

Conclusion: Anatomical outcomes and central visual function improved or remained stable in the three AMD patients in concordance with past reports. Further investigations of possible adverse effects of ranibizumab on the central and peripheral neuroretina in large prospective clinical trials are suggested.

Impact and interest:

Citation countsare sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 12431
Item Type: Journal Article
Additional Information: For more information, please refer to the journal’s website (see hypertext link) or contact the author.
Additional URLs:
Keywords: age, related macular degeneration, optical coherence tomography, OCT, multifocal electroretinogram, multifocal ERG, ranibizumab
Subjects: Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > OPTOMETRY AND OPHTHALMOLOGY (111300)
Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > OPTOMETRY AND OPHTHALMOLOGY (111300) > Vision Science (111303)
Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > OPTOMETRY AND OPHTHALMOLOGY (111300) > Optical Technology (111302)
Divisions: Current > Research Centres > Centre for Health Research
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
Copyright Owner: Copyright DOVE Medical Press
Deposited On: 13 Feb 2008
Last Modified: 29 Feb 2012 23:37

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page